Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients

A. Gouchi, S. Fuchimoto, K. Orita, E. Konaga, T. Mannami, S. Okamura, K. Satoh, T. Ohhara, N. Ogawa

Research output: Contribution to journalArticle

Abstract

Many BRMs (Biological Response Modifiers) have been used for postoperative chemoimmunotherapy, and their usefulness was also reported. But these results were not satisfactory, and randomized studies were tried. Then we attempted a study to confirm the efficacy of preoperative intratumoral injection of OK- 432 for advanced gastric patients. In all, 395 cases were entered in the study and randomized according to preoperative diagnosis. In these cases, early gastric cancer cases were excluded, 277 cases were evaluable, 145 were preoperative OK-432 injected (group A), and 132 cases were control (group B). The five year survival rate was improved in group A, especially in stage IIIa, n2(+) and negative reaction of PPD. According to multi-valent analysis, the effect of lymph node metastasis, which was one of the important prognostic factors, was lower in group A than in group B. These results suggest that preoperative intra-tumoral OK-432 injection reduced the metastatic rate and improved the postoperative survival rate.

Original languageEnglish
Pages (from-to)50-59
Number of pages10
JournalBiotherapy
Volume10
Issue number1
Publication statusPublished - 1996

Fingerprint

Picibanil
Stomach Neoplasms
Survival Rate
Injections
Tuberculin
Immunologic Factors
Stomach
Lymph Nodes
Neoplasm Metastasis
Control Groups

Keywords

  • Intratumoral injection
  • Medical lymphadenectomy
  • OK-432

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Gouchi, A., Fuchimoto, S., Orita, K., Konaga, E., Mannami, T., Okamura, S., ... Ogawa, N. (1996). Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients. Biotherapy, 10(1), 50-59.

Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients. / Gouchi, A.; Fuchimoto, S.; Orita, K.; Konaga, E.; Mannami, T.; Okamura, S.; Satoh, K.; Ohhara, T.; Ogawa, N.

In: Biotherapy, Vol. 10, No. 1, 1996, p. 50-59.

Research output: Contribution to journalArticle

Gouchi, A, Fuchimoto, S, Orita, K, Konaga, E, Mannami, T, Okamura, S, Satoh, K, Ohhara, T & Ogawa, N 1996, 'Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients', Biotherapy, vol. 10, no. 1, pp. 50-59.
Gouchi A, Fuchimoto S, Orita K, Konaga E, Mannami T, Okamura S et al. Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients. Biotherapy. 1996;10(1):50-59.
Gouchi, A. ; Fuchimoto, S. ; Orita, K. ; Konaga, E. ; Mannami, T. ; Okamura, S. ; Satoh, K. ; Ohhara, T. ; Ogawa, N. / Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients. In: Biotherapy. 1996 ; Vol. 10, No. 1. pp. 50-59.
@article{acf6a5cb2703422899db7b44032c0e9c,
title = "Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients",
abstract = "Many BRMs (Biological Response Modifiers) have been used for postoperative chemoimmunotherapy, and their usefulness was also reported. But these results were not satisfactory, and randomized studies were tried. Then we attempted a study to confirm the efficacy of preoperative intratumoral injection of OK- 432 for advanced gastric patients. In all, 395 cases were entered in the study and randomized according to preoperative diagnosis. In these cases, early gastric cancer cases were excluded, 277 cases were evaluable, 145 were preoperative OK-432 injected (group A), and 132 cases were control (group B). The five year survival rate was improved in group A, especially in stage IIIa, n2(+) and negative reaction of PPD. According to multi-valent analysis, the effect of lymph node metastasis, which was one of the important prognostic factors, was lower in group A than in group B. These results suggest that preoperative intra-tumoral OK-432 injection reduced the metastatic rate and improved the postoperative survival rate.",
keywords = "Intratumoral injection, Medical lymphadenectomy, OK-432",
author = "A. Gouchi and S. Fuchimoto and K. Orita and E. Konaga and T. Mannami and S. Okamura and K. Satoh and T. Ohhara and N. Ogawa",
year = "1996",
language = "English",
volume = "10",
pages = "50--59",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "1",

}

TY - JOUR

T1 - Randomized controlled study of preoperative intratumoral OK-432 administration for gastric cancer patients

AU - Gouchi, A.

AU - Fuchimoto, S.

AU - Orita, K.

AU - Konaga, E.

AU - Mannami, T.

AU - Okamura, S.

AU - Satoh, K.

AU - Ohhara, T.

AU - Ogawa, N.

PY - 1996

Y1 - 1996

N2 - Many BRMs (Biological Response Modifiers) have been used for postoperative chemoimmunotherapy, and their usefulness was also reported. But these results were not satisfactory, and randomized studies were tried. Then we attempted a study to confirm the efficacy of preoperative intratumoral injection of OK- 432 for advanced gastric patients. In all, 395 cases were entered in the study and randomized according to preoperative diagnosis. In these cases, early gastric cancer cases were excluded, 277 cases were evaluable, 145 were preoperative OK-432 injected (group A), and 132 cases were control (group B). The five year survival rate was improved in group A, especially in stage IIIa, n2(+) and negative reaction of PPD. According to multi-valent analysis, the effect of lymph node metastasis, which was one of the important prognostic factors, was lower in group A than in group B. These results suggest that preoperative intra-tumoral OK-432 injection reduced the metastatic rate and improved the postoperative survival rate.

AB - Many BRMs (Biological Response Modifiers) have been used for postoperative chemoimmunotherapy, and their usefulness was also reported. But these results were not satisfactory, and randomized studies were tried. Then we attempted a study to confirm the efficacy of preoperative intratumoral injection of OK- 432 for advanced gastric patients. In all, 395 cases were entered in the study and randomized according to preoperative diagnosis. In these cases, early gastric cancer cases were excluded, 277 cases were evaluable, 145 were preoperative OK-432 injected (group A), and 132 cases were control (group B). The five year survival rate was improved in group A, especially in stage IIIa, n2(+) and negative reaction of PPD. According to multi-valent analysis, the effect of lymph node metastasis, which was one of the important prognostic factors, was lower in group A than in group B. These results suggest that preoperative intra-tumoral OK-432 injection reduced the metastatic rate and improved the postoperative survival rate.

KW - Intratumoral injection

KW - Medical lymphadenectomy

KW - OK-432

UR - http://www.scopus.com/inward/record.url?scp=0030068583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030068583&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030068583

VL - 10

SP - 50

EP - 59

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 1

ER -